Empresa Melinta Therapeutics Inc Nasdaq
Acciones
US58549G1004
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 48 | 03/08/20 | |
Susan Blum
DFI | Director of Finance/CFO | 52 | 01/01/16 |
Compliance Officer | 45 | - | |
Jisoo Park
PRN | Corporate Officer/Principal | - | 06/07/21 |
Kristen Allgor
HRO | Human Resources Officer | - | 16/11/20 |
John Harlow
PRN | Corporate Officer/Principal | - | 30/03/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20/04/20 |
Director/Board Member | - | 20/04/20 | |
Director/Board Member | - | 20/04/20 | |
Compliance Officer | 45 | - | |
Chief Executive Officer | 48 | 03/08/20 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 13 750 691 | 13 578 334 ( 98,75 %) | 0 | 98,75 % |
Información de la empresa
Melinta Therapeutics, Inc.
389 Interpace Parkway Suite 450
07054, Parsippany
+908-617-1300
http://melinta.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+5,28 % | 109 mil M | |
+11,27 % | 105 mil M | |
-0,38 % | 22,25 mil M | |
-12,08 % | 22,09 mil M | |
-7,66 % | 18,68 mil M | |
-36,52 % | 17,58 mil M | |
-10,36 % | 16,85 mil M | |
+2,87 % | 13,76 mil M | |
+35,80 % | 12,46 mil M |